Catheter Precision, Inc. VTAK
0.15
(0.01)
(6.25%)
as of 25 Sep
- Market cap
- $3.0M
- P/E
- 0.0×
Follow VTAK
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.03 |
+8 more quarters Free account |
P/S ratio |
1.23 | 2.00 | 2.41 | 4.56 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.82) | (0.79) | (1.31) | (1.52) | |
P/B ratio |
0.14 | 0.24 | 0.30 | 0.52 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.01 | 4.55 | 6.13 | 3.59 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.41) | (0.58) | (0.60) | (0.27) | |
EV/FCF |
(0.41) | (0.57) | (0.60) | (0.27) | |
Quick Ratio |
0.15 | 0.04 | 0.06 | 0.41 | |
Current Ratio |
0.19 | 0.06 | 0.10 | 0.46 | |
Net Debt/EBITDA |
(0.44) | (1.53) | (0.32) | 0.30 | |
Debt/Assets |
8.92% | 9.16% | 19.41% | 5.09% | |
Debt/Equity |
0.19 | 0.35 | 0.46 | 0.20 | |
Asset Turnover |
0.06 | 0.04 | 0.04 | 0.03 | |
Operating CF/Net income |
1.12 | 0.92 | 0.26 | 0.97 | |
Capex/Depreciation |
(0.02) | (0.01) | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
13.94% | 34.49% | 137.82% | 122.12% | |
Selling, General and Administrative Expense of Revenue |
383.81% | 592.36% | 1,157.98% | 1,306.64% | |
Intangible Assets out of Total Assets |
0.86 | 0.91 | 0.96 | 0.89 | |
Share Based Compensation of Revenue |
26.10% | 14.81% | 33.19% | 30.97% | |
Graham Net Nets |
(7.32) | (11.15) | (4.46) | (4.98) | |
Graham Number |
0.00 | 0.00 | 0.00 | 104.77 | |
Earnings Yield |
(810.59%) | (1,306.37%) | (1,019.04%) | 3,964.10% | |
Free Cash Flow Yield |
(398.46%) | (396.03%) | (420.38%) | (290.42%) | |
Revenue per Share |
0.37 | 0.20 | 0.22 | 0.17 | |
Operating CF per Share |
(1.03) | (1.28) | (1.40) | (1.65) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.04) | (1.28) | (1.40) | (1.65) | |
Cash per Share |
0.66 | 0.20 | 0.08 | 1.56 | |
Shareholders Equity per Share |
6.19 | 4.18 | 6.15 | 4.88 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.19 | 4.18 | 6.15 | 4.88 | |
Free Cash Flow |
(2.88) | (2.80) | (1.51) | (2.18) | |
Working Capital |
(10.94) | (18.49) | (3.52) | (2.86) | |
Capital Expenditures |
(0.01) | (0.01) | 0.00 | 0.00 | |
Net Current Asset Value |
(17.22) | (24.68) | (8.82) | (16.56) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.00 | |
Net Profit Margin |
(250.74%) | (703.94%) | (2,427.73%) | (996.02%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.12 | 0.17 | 0.11 | 0.12 | |
Average Payables |
1.13 | 0.86 | 0.86 | 0.89 | |
Average Inventory |
0.07 | 0.07 | 0.06 | 0.03 | |
Average Assets |
31.22 | 29.94 | 21.82 | 26.11 | |
Average Common Equity |
11.84 | 8.54 | 9.20 | 9.64 |
Columns are period end dates